Expert Ratings for ResMed
Portfolio Pulse from Benzinga Insights
ResMed (NYSE:RMD) has received a mix of bullish and indifferent analyst ratings in the last quarter, with no bearish ratings. The average price target is $231.3, indicating potential upside from the current price of $141.0. However, this average has decreased by 13.08% from the previous target of $266.12.
October 12, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ResMed has received mostly bullish and indifferent ratings from analysts, with an average price target indicating potential upside. However, the decrease in the average target could impact investor sentiment.
Analyst ratings can significantly influence investor sentiment and stock price. While the bullish and indifferent ratings for ResMed are positive, the decrease in the average price target could be seen as a negative signal, potentially leading to uncertainty in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100